Hypogonadism
Conditions
Brief summary
Hypogonadal males, particularly those whose condition manifested later in life, may experience common symptoms associated with their hypogonadism. Questionnaires developed to assess these symptoms need to be tested. The primary purpose of this study is to test or validate the Patient-Reported Symptom Measure, Androgen Deficiency Quality of Life Questionnaire and the Patient Global Impression Scale.
Interventions
DRUGTestim 1% (testosterone gel)
Testim\_ 100 mg: two tubes of 50 mg of Testim\_per day
DRUGPlacebo
two tubes of placebo per day
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
50 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
Men with late-onset hypogonadism who are either on testosterone treatment or naïve of treatment: * have symptoms of androgen deficiency at screening (after wash-out if applicable) i.e. with a positive score on the Androgen Deficiency in the Aging Male (ADAM) Questionnaire (a yes answer to questions 1 or 7 or any three other questions). * morning total T levels of \<=3 ng/mL (\<=300 ng/dL; \<=10.4 nmol/l) on two separate days prior to randomization (after appropriate wash-out, if applicable). * calculated free T \<=0.074 ng/mL. * at least 50 and at most 75 years of age. * BMI of at least 18 kg/m\^2 or at most 32 kg/m\^2 Inclusion Criteria for Normogonadal Men: * morning total T levels \<=3 ng/mL (\<=300 ng/dL; \<=10.4 nmol/L). * calculated free T \<=0.074 ng/mL. * at least 50 and at most 75 years of age. * BMI of at least 18 kg/m\^2 or at most 32 kg/m\^2
Exclusion criteria
* History or current diagnosis of prostate cancer or any clinically significant finding on prostate examination * Severe obstructive symptoms of benign prostate hypertrophy * Prostate specific antigen (PSA) levels greater than 4 ng/mL at screening * History or current diagnosis of carcinoma of the breast * Known chronic polycythemia and/or hematocrit greater than 50% at screening * Treatment-naïve subjects with hyperprolactinemia at screening (serum prolactin level \>=50 ng/mL) * Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator * clinically significant abnormal physical finding prior to randomization * sensitive to trial medication or its components * History or presence of hepatic or renal disorder considered as clinically relevant in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient -reported outcome measures | Baseline and after six weeks of treatment or placebo |
Outcome results
None listed